The study confronts a critical gap in our understanding of how Mpox virus manifests in individuals with compromised immune systems, a demographic increasingly relevant in current public health scenarios amid overlapping viral epidemics. Employing a meticulous experimental model, rhesus macaques were first infected with SIVmac239, a pathogenic clone of SIV that mirrors human immunodeficiency virus (HIV) infection in its immunosuppressive profile. Subsequent Mpox virus inoculation enabled researchers to simulate viral co-infection dynamics analogous to those potentially encountered in immunocompromised human hosts.

Central to this investigation is the utilization of cutting-edge proteomic technologies to obtain multi-organ profiles that map the proteome-wide alterations induced by Mpox virus during co-infection. These advanced methodologies allowed for the identification of specific protein expression changes across diverse anatomical compartments, revealing that the virus does not merely cause localized pathology but triggers systemic deregulation of key biological pathways. Proteomic shifts were particularly pronounced in lymphoid tissues, lungs, liver, and gastrointestinal tract, aligning with clinical manifestations often observed in severe poxviral infections.

The proteomic data uncovered a cascade of immune response modulations, including aberrant activation of inflammatory mediators and dysregulation of antiviral signaling pathways. Notably, the co-infected rhesus macaques exhibited a disrupted balance in cytokine production, with heightened levels of pro-inflammatory cytokines such as IL-6, TNF-α, and IFN-γ, which collectively contribute to pathogenic inflammation. This protracted inflammatory milieu likely exacerbates tissue damage and facilitates viral dissemination beyond primary sites of infection.

Equally revealing was the observation that Mpox virus infection in the context of SIV co-infection led to marked alterations in metabolic pathways, implicating impaired cellular energetics and redox states as contributing factors to disease progression. Proteomic signatures indicated suppression of mitochondrial function and an increased presence of oxidative stress markers, implicating these cellular dysfunctions as key drivers of the observed multi-organ pathology. These findings provide a molecular foundation for understanding the systemic deterioration observed in severe Mpox virus infections exacerbated by immunosuppression.

Moreover, the study highlights the virus’s ability to subvert host antiviral defenses by downregulating critical components of the interferon-stimulated gene (ISG) network. This evasion strategy undermines early innate immune responses, potentially allowing unchecked viral replication during the initial stages of infection. Coupled with impaired adaptive immunity due to SIV-mediated CD4+ T-cell depletion, the virus exploits an immunocompromised environment to amplify its pathogenic potential.

Interestingly, the histopathological analyses conducted alongside proteomic assessments revealed extensive tissue damage characterized by necrosis, infiltration of inflammatory cells, and evidence of viral antigen presence across multiple organs. Such pathological hallmarks mirror clinical observations in human cases of Mpox, particularly in immunosuppressed individuals, reinforcing the translational relevance of the macaque model for studying disease mechanisms and therapeutic interventions.

Investigating the temporal dynamics of the infection, the researchers documented a progressive escalation of proteomic abnormalities over the course of infection, with early alterations in immune cell signaling pathways preceding widespread tissue pathology. This temporal resolution underscores the importance of early detection and intervention to curb the systemic spread and severe outcomes associated with Mpox virus infection in vulnerable populations.

The implications of these findings reach beyond the immediate viral pathogenesis, touching upon broader themes of host-pathogen interactions, immune senescence, and viral evolution in immunocompromised milieus. By illuminating the proteomic landscape that underpins Mpox virus infection during SIV-induced immunodeficiency, the study paves the way for targeted therapeutic approaches aimed at modulating host immune responses, ameliorating inflammation, and restoring metabolic homeostasis.

Importantly, this research also raises critical questions about viral transmission dynamics and the potential for increased viral shedding in immunocompromised hosts. The heightened systemic viral load and multifocal tissue involvement observed suggest that co-infected individuals could serve as enhanced reservoirs for viral persistence and dissemination, emphasizing the need for tailored public health strategies in outbreaks where immunosuppressive conditions prevail.

On a methodological level, the integration of proteomic technologies with classical virology and immunopathology exemplifies the power of interdisciplinary approaches to unravel complex biological phenomena. The comprehensive multi-organ analysis employed here offers a robust blueprint for future investigations into other viral co-infections and their systemic consequences, highlighting the necessity of systems-level understanding in infectious diseases research.

From a clinical perspective, these insights advocate for vigilant monitoring of Mpox virus infection in patients with underlying immunodeficiencies, including those living with HIV/AIDS or undergoing immunosuppressive therapies. The molecular signatures identified could inform biomarker development for disease severity and progression, facilitating personalized management strategies that address both viral and host factors.

Furthermore, the study contributes to the broader discourse on emerging zoonoses and the challenges posed by viral spillover events into immunologically vulnerable populations. As Mpox virus continues to garner global attention due to its epidemic potential, elucidating the factors that drive severe disease manifestations is paramount to informing vaccine strategies, antiviral development, and public health preparedness.

In conclusion, this landmark investigation provides a detailed proteomic atlas of Mpox virus infection in an immunocompromised primate model, unveiling the multifactorial mechanisms of viral pathogenesis across organ systems. The synergy between viral immune evasion, inflammatory dysregulation, and metabolic disruption delineated here not only advances fundamental understanding but also holds transformative potential for the development of targeted interventions in vulnerable patient populations. As infectious disease threats intensify in complexity, such integrative studies underscore the imperative of holistic biological inquiry to safeguard global health.

Subject of Research: The pathogenicity and multi-organ proteomic profiling of Mpox virus infection in rhesus macaques co-infected with simian immunodeficiency virus (SIVmac239).

Article Title: The pathogenicity and multi-organ proteomic profiles of Mpox virus infection in SIVmac239-infected rhesus macaques.

Article References:

Zhang, D., Liu, J., Zhu, L. et al. The pathogenicity and multi-organ proteomic profiles of Mpox virus infection in SIVmac239-infected rhesus macaques.
Nat Commun 16, 7653 (2025). https://doi.org/10.1038/s41467-025-62919-z

Image Credits: AI Generated

Mpox, formerly known as monkeypox, has posed increasing public health challenges due to its zoonotic origins and capacity for human infection. Traditional vaccine strategies have often relied on live-attenuated or inactivated viral constructs, which, while effective, present safety concerns and logistical hurdles in production and distribution. The innovative use of virus-like nanoparticles (VLPs) circumvents many of these obstacles by mimicking the native viral architecture without containing infectious genetic material, thereby offering a safer and potentially more immunogenic alternative.

The study meticulously engineered a multiprotein nanoparticle that structurally and antigenically mimics the Mpox virus. By assembling multiple viral proteins into a singular nanoparticle, the vaccine candidate presents an array of epitopes capable of eliciting a broad and robust immune response. This multivalent presentation is key to its enhanced immunogenicity, as it effectively mimics the conformational complexity of the authentic virus, which is crucial for inducing neutralizing antibodies targeting diverse viral components.

Delving deeper into the vaccine’s design, the researchers employed recombinant protein technology to produce individual Mpox viral proteins that were then self-assembled into nanoparticles. This self-assembly process is driven by precise biochemical interactions, ensuring that the final structure maintains the antigenic integrity necessary for immune system recognition. This technology leverages state-of-the-art protein engineering methods, enabling the display of multiple antigens in a highly ordered and repetitive array that mimics the authentic virus’ surface, a factor known to enhance B cell receptor cross-linking and potentiate a strong humoral response.

In preclinical evaluation, the multiprotein VLP vaccine was administered to mouse models, eliciting high titers of neutralizing antibodies that effectively blocked viral infection in vitro. These antibodies demonstrated cross-reactivity not only against Mpox but also against related orthopoxviruses, underscoring the vaccine’s potential for broad-spectrum protection. This cross-neutralization capability is particularly significant in light of emerging viral variants and the ever-present risk of zoonotic spillover events.

Moving beyond rodent models, the vaccine’s efficacy was tested in non-human primates, which closely recapitulate human immune responses. Remarkably, vaccinated primates exhibited robust neutralizing antibody responses alongside potent protection from viral challenge, marked by both reduced viral loads and attenuated clinical symptoms. This dual evidence of immunogenicity and protection positions the vaccine candidate as a strong contender for advancing into human clinical trials.

A notable feature of the VLP approach is its versatility. The modular nature of nanoparticle assembly permits rapid adaptation to emerging viral threats by incorporating novel antigenic components without overhauling the entire vaccine platform. This technological flexibility equips researchers with a powerful tool to respond swiftly to viral evolution and outbreaks, an indispensable asset in the current landscape of infectious diseases.

Furthermore, the safety profile of the nanoparticle vaccine is promising. By excluding viral genetic materials, the risk of vaccine-derived infection or reversion is eliminated. The study reports no significant adverse effects in vaccinated subjects, highlighting the nanoparticle’s biocompatibility and the potential for improved vaccine tolerability compared to traditional platforms.

The immunological mechanisms underlying the vaccine’s efficacy extend beyond mere antibody production. The VLPs were found to efficiently stimulate antigen-presenting cells, leading to enhanced T cell activation and memory formation. This comprehensive activation of both arms of adaptive immunity is vital for sustained protection, particularly against viruses capable of evading or suppressing immune responses.

The study also sheds light on the physicochemical properties essential for vaccine performance. The stability of the nanoparticles under physiological conditions contributes to the prolonged presentation of antigens to the immune system, fostering a durable immune response. Additionally, the ordered repetitive antigen display enhances B cell receptor engagement, a critical factor in generating high-affinity antibodies through germinal center reactions.

In a global context, the development of such a multiprotein VLP vaccine aligns with the increasing demand for next-generation vaccines that balance efficacy, safety, and manufacturability. By harnessing synthetic biology and protein engineering, this approach may reduce reliance on cold chain logistics and enable scalable production, facilitating deployment in resource-limited settings prone to Mpox outbreaks.

The translational potential of this vaccine extends beyond Mpox. The underlying principles – multivalent antigen presentation, nanoparticle-based delivery, and safety without live virus – are applicable to a broad range of viral pathogens. This opens avenues for designing universal or pan-virus vaccines capable of targeting multiple strains or related viruses through a single immunogen.

Ongoing investigations aim to elucidate the full spectrum of immune correlates induced by the vaccine, including the longevity of antibody responses and the quality of T cell memory. Such insights will inform dosing regimens, booster strategies, and combinatorial use with other immunomodulatory agents to optimize protective efficacy.

The integration of advanced immunoprofiling techniques, such as single-cell transcriptomics and high-dimensional flow cytometry, is poised to deepen the understanding of host-pathogen interactions modulated by the VLP vaccine. Future studies may also explore the potential for mucosal immunity induction, critical for preventing initial viral entry and transmission.

As the field moves forward, regulatory pathways for nanoparticle vaccines are becoming increasingly defined, with several precedents established by existing VLP-based vaccines against other viruses. This regulatory clarity bodes well for the streamlined advancement of the Mpox multiprotein VLP vaccine into rigorous clinical evaluation phases.

In summary, the study by Belghith and colleagues marks a pivotal advancement in virology and vaccinology, showcasing the promise of multiprotein virus-like nanoparticle vaccines to confer potent and broad protection against emerging viral pathogens. With continued multidisciplinary collaboration and rapid translational efforts, this innovation may soon materialize as a critical tool in the global armamentarium against Mpox and other orthopoxvirus threats.

Subject of Research: Development and evaluation of a multiprotein virus-like nanoparticle vaccine targeting Mpox, focusing on eliciting neutralizing and protective antibodies in preclinical animal models.

Article Title: Mpox multiprotein virus-like nanoparticle vaccine induces neutralizing and protective antibodies in mice and non-human primates.

Article References: Belghith, A.A., Cotter, C.A., Ignacio, M.A. et al. Mpox multiprotein virus-like nanoparticle vaccine induces neutralizing and protective antibodies in mice and non-human primates. Nat Commun 16, 4726 (2025). https://doi.org/10.1038/s41467-025-59826-8

Image Credits: AI Generated

As highlighted in a letter to the esteemed journal Nature Medicine, scientists from Surrey have documented a notable uptick in intimate human interactions as a primary mode of transmission. Carlos Maluquer de Motes, a Reader in Molecular Virology, illuminates this shift, emphasizing that the contemporary outbreaks signify a change in mpox transmission pathways, which now include significant person-to-person contact. The delineation of these transmission chains is crucial as it directly correlates with the potential for lasting outbreaks that could impact a much larger population.

A detailed analysis of the mpox virus reveals its association with the orthopoxvirus genus, the same virus family that includes smallpox. Notably, the clinical manifestations of mpox mirror those of smallpox, albeit often milder, presenting with notable symptoms such as a painful rash, fever, swollen lymph nodes, and malaise. Understanding mpox’s clinical landscape is vital, as its potential to evolve into a more aggressive variant poses a risk not only to adults but to vulnerable populations, including children.

Research indicates that the current surge in mpox infections has been linked to clade IIb variants, which are suggested to be more transmissible. However, scientists have also observed a resurgence of clade I variants, which are perceived to exhibit more aggressive behavior. This finding underscores a crucial area of concern, as the ongoing genetic mutations within these viruses, resulting from their interaction with human enzymes, could facilitate adaptation mechanisms that enhance the virus’s ability to thrive in human populations.

The epidemiology of mpox has transformed dramatically over recent years. The traditional narrative, which associated the virus primarily with remote regions of Central Africa, has evolved. In 2022, mpox outbreaks transcended geographic boundaries, triggering an international health alert. The multifaceted spread has prompted health authorities to rethink their strategies, particularly concerning surveillance, diagnostics, and treatment provisions, which, as it stands, remain critically limited.

One of the striking observations made by the Surrey researchers is the implication of sexual networks in the facilitation of mpox’s transmission. Dr. Maluquer de Motes elaborates on this point, noting that intimate contact has become a predominant vector for not only sexual partners but also close-knit communities. This noteworthy alteration in mpox dynamics necessitates an urgent reevaluation of public health messaging and intervention strategies, particularly in enhancing community awareness and education.

Amidst this evolving landscape, there are rising concerns linked to the accessibility of effective diagnostics and the availability of antiviral treatments. Presently, the tools at our disposal for mpox management are insufficient, which complicates the response to outbreak investigations and control efforts. The call for better-synchronized global health initiatives is becoming increasingly urgent as the potential for future epidemics looms larger on the horizon.

In light of mpox’s capacity to persist in animal reservoirs—differentiating it from eradicated viruses such as smallpox—health experts advocate for immediate, coordinated international action. It is evident that without investment in novel point-of-care testing and the development of new antiviral therapies, we risk entering a cycle of recurrent epidemics, each potentially more severe than the last. This scenario emphasizes the necessity of enhanced global health infrastructures, which can facilitate the rapid detection and treatment of mpox outbreaks.

Children represent a particularly vulnerable demographic in the context of mpox transmission and illness. Although sustained transmission among children has yet to be documented, the potential for mpox to affect younger populations cannot be disregarded. Historical patterns of viral infection reiterate the susceptibility of children to severe illness, particularly in the absence of robust health care frameworks. Public health approaches must prioritize research designed to protect this vulnerable group, ensuring that educational resources are meticulously crafted and disseminated.

In the sphere of virology and epidemiology, the emerging understanding of mpox not only challenges current paradigms of infectious disease management but also underscores the intricate interplay between viral evolution and public health policies. Continuous research into the genetic makeup of mpox viruses promises to yield insights that could illuminate optimal intervention strategies, potentially shoring up defenses against both current and emergent infectious threats.

The need for comprehensive surveillance and community health initiatives is paramount. Localized efforts, coupled with international collaboration, are key to addressing the multifaceted challenges posed by mpox. By promoting better awareness and understanding of the virus and its transmission modes, a more informed global populace can be fostered, which is essential for curbing the spread and impact of this viral infection.

As researchers at the University of Surrey and beyond continue to unravel the complexities of mpox, a collective commitment to proactive public health measures can empower communities to face this evolving health threat head-on. The urgency of the situation cannot be overstated, and it is crucial for stakeholders at all levels—government agencies, healthcare professionals, and communities—to unite in a concerted effort to mitigate the risks and safeguard public health.

Subject of Research: Mpox and its implications for global health
Article Title: Mpox poses an ever-increasing epidemic and pandemic risk
News Publication Date: 1-Apr-2025
Web References: http://dx.doi.org/10.1038/s41591-025-03589-8
References: Nature Medicine
Image Credits: University of Surrey
Keywords: Infectious diseases; Viral infections; Monkeypox; Health and Medicine; Epidemiology